Dr. Yoland Catherine Antill on Results of the PHAEDRA Trial

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Cancer Network spoke with Yoland Catherine Antill, MD, of Cabrini Health, about the phase II PHAEDRA trial, which tested the activity of durvalumab in advanced endometrial cancer according to mismatch repair status.

Cancer Network spoke with Yoland Catherine Antill, MD, of Cabrini Health, about the phase II PHAEDRA trial, which tested the activity of durvalumab in advanced endometrial cancer according to mismatch repair status.

Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Ritu Salani, MD, discussed investigational endometrial cancer treatment options for patients with varying subtypes of endometrial cancer.
The second interim analysis of the phase 3 RUBY trial found the safety profile was consistent with the first interim analysis and no new deaths due to AEs were observed.
Related Content
Barriers and gaps in treatment and care for patients diagnosed with gynecologic cancers were reported in a recent survey.

Survey Says Gaps Exist in Gynecologic Cancer Treatment

Tim Cortese
November 15th 2024
Article

Barriers and gaps in treatment and care for patients diagnosed with gynecologic cancers were reported in a recent survey.

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

John Paul Diaz, MD
November 4th 2024
Podcast

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Ginger J. Gardner, MD, FACOG, walked through the strides of gynecologic cancer research and emphasized the efforts that still need to be accomplished.

Despite Great Strides, Much Work Remains in GYN Cancer Outcomes and Care

Gina Mauro
October 16th 2024
Article

Ginger J. Gardner, MD, FACOG, walked through the strides of gynecologic cancer research and emphasized the efforts that still need to be accomplished.

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Empowering Awareness to Address Rising Gynecological Cancer Incidence

Ginger J. Gardner, MD, FACOG
October 28th 2024
Podcast

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Improving Sexual Health After Gynecological Cancer Is a Multifaceted Approach

Improving Sexual Health After Gynecological Cancer Is a Multifaceted Approach

Ariana Pelosci;Gina Mauro
September 20th 2024
Article

Pluta Cancer Center clinicians discussed how to improve sexual health outcomes for patients diagnosed with gynecological cancer.

Deep and durable responses were observed with lenvatinib plus pembrolizumab in patients with stage III/IV recurrent endometrial carcinoma.

Lenvatinib Combo Yields Substantial Antitumor Activity in Endometrial Cancer

Roman Fabbricatore
September 18th 2024
Article

Deep and durable responses were observed with lenvatinib plus pembrolizumab in patients with stage III/IV recurrent endometrial carcinoma.